Loading stock data…
$53.07+1.27 (+2.45%)
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Travere Therapeutics, Inc. in the Healthcare sector is trading at $53.07 with a market capitalization of $5.9B. Wall Street consensus targets $75.21 (14 analysts), implying a +41.7% move over the next 12 months. The stock is currently 23% below its 52-week high of $68.73, remaining 16.2% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $169.58M↑ | $127.20M↓ | $129.69M↓ | $164.86M↑ | $114.45M |
| Gross Profit | $160.35M↑ | $100.43M↓ | $127.14M↓ | $163.27M↑ | $99.29M |
| Operating Income | $3.95M↑ | -$36.91M↓ | -$32.43M↓ | $24.93M↑ | -$12.65M |
| Net Income | -$34.80M↑ | -$37.10M↓ | $2.73M↓ | $25.71M↑ | -$12.76M |
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, o...